GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sanofi-aventis Sa (SNY) [hlAlert]

Rating:
Buy SNY
up 43.74 %

Barron's Favorite Stocks for 2012 - Sanofi

Posted on: Thursday,  Jan 3, 2013  1:23 AM ET by Barron's favorite stocks for 2012

Barron's favorite stocks for 2012 rated Buy Sanofi-aventis Sa (NYSE: SNY) on 12/12/2011, when the stock price was $34.84.
Since then, Sanofi-aventis Sa has gained 43.74% as of 01/26/2016's recent price of $50.08.
If you would have followed this Barron's favorite stocks for 2012's recommendation on SNY, you would have gained 43.74% of your investment in 1506 days.

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither. In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

After a volatile year, stocks are heading into the homestretch about where they began. The benchmark Standard & Poor's 500 Index finished the week at 1255, within a percentage point of where it started the year. The Dow Jones Industrial Average is up 5% in 2011, largely reflecting the strength of a single stock, IBM (ticker: IBM), which has risen 32% to 194 and dominates the price-weighted index owing to its lofty absolute share price. Most equity strategists are optimistic at best about 2012. They're worried that earnings growth and strong corporate balance sheets will be offset, in investors' minds, by the tough economic backdrop and the European debt crisis. Barry Knapp, Barclays Capital's chief market strategist, recently set an S&P 500 target of 1330, 6% above Friday's close. He expects a "difficult" first half followed by a second-half rally. The important offset to the economic and political situation is valuation. U.S. stocks look reasonably priced, especially with 10-year Treasuries yielding 2% and short-term rates near zero. The S&P 500 is valued at 13 times projected 2011 profits and about 12 times next year's projected earnings. Bulls cite the combination of attractive valuations and super-low rates. "I feel like a kid in a candy store…I don't know where to begin," said Joe Rosenberg, chief investment strategist at Loews, told Barron's in last week's interview ("The Best Opportunities in a Half-Century," Dec. 5). Rosenberg is partial to a range of blue-chip stocks.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/12/2011 4:00 PM Buy
1 year
34.84
as of 8/27/2015
1 Week down  -1.26 %
1 Month down  -2.20 %
3 Months down  -1.39 %
1 YTD down  -6.61 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy